Onconetix, Inc. (ONCO)
About Onconetix, Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $815.4K
- Net income
- -$14.0M
- Total assets
- $24.9M
- Market cap
- $1.2M
- Gross margin
- 77.6%
- Operating margin
- -2190.0%
- Net margin
- -1721.0%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $815.4K
- Cost of revenue
- $182.5K
- Gross profit
- $632.9K
- Operating expenses
- $18.5M
- Operating income
- -$17.9M
- Income tax
- $525
- Net income
- -$14.0M
- EPS (basic)
- $-16.56
- EPS (diluted)
- $-16.56
Balance sheet
- Total assets
- $24.9M
- Current assets
- $6.1M
- Total liabilities
- $9.2M
- Current liabilities
- $9.1M
- Shareholders’ equity
- $15.8M
Cash flow
- Operating cash flow
- -$9.7M
- Investing cash flow
- -$4.6M
- Financing cash flow
- $14.5M
- Net cash flow
- $200.1K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.2M
- EPS (diluted)
- $-16.56
- Shares outstanding
- 1.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 18, 2022
Onconetix, Inc. (ONCO) Stock Price
- Reported a net loss of $14.0M in FY2025.
- Revenue grew 1295% from FY2023 to FY2025.
- Gross margin of 77.6%, net margin -1721.0%.
- Trading 100% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Onconetix, Inc..
Write a review
News about Onconetix, Inc.
News & sentiment via Polygon.io
Onconetix, Inc.: frequently asked questions
Is Onconetix, Inc. an American company?
Onconetix, Inc. is a US-based company headquartered in Cincinnati, Ohio, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Onconetix, Inc. headquartered?
Onconetix, Inc. is headquartered in Cincinnati, Ohio, United States.
Is Onconetix, Inc. publicly traded?
Yes — Onconetix, Inc. is a publicly traded company. Its stock trades under the ticker symbol ONCO on the NASDAQ.
What does Onconetix, Inc. do?
Onconetix, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
